DYAX, FADV, TAST, SNTS, VVTV, DRRX Expected To Be Lower Leading Up To Next Earnings Releases
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed before their last 12 quarterly, 6 quarterly and July/August earnings reports. Dyax Corp (NASDAQ: DYAX), First Advantage (NASDAQ: FADV), Carrols Restaurant Group (NASDAQ: TAST), Santarus (NASDAQ: SNTS), Value Vision Media (NASDAQ: VVTV) and DURECT Corp (NASDAQ: DRRX) are all expected to be lower leading up to their next earnings release. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act before its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php. The following stocks are expected to go lower leading up to their next earnings release:
Symbol Company # of Releases Quarter Release Date
DYAX Dyax Corporation 12 quarters Q2 7/22/2009
FADV First Advantage Corp 12 quarters Q2 7/27/2009
TAST Carrols Restaurant 12 quarters Q2 8/3/2009
SNTS Santarus Inc. 12 quarters Q2 8/4/2009
VVTV ValueVision Media Inc. 12 quarters Q2 8/18/2009
DRRX DURECT Corporation 12 quarters Q2 8/4/2009
Earnings, or profits, drive stock prices. The market values a company based on its current and anticipated future ability to make money. The market takes the earnings pulse of a company four times per year when quarterly reports are issued. When this information is released it can often be a trend-changing or a trend confirming event. because the information is so vital to the market's perception of the vitality of that company.
This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.
Dyax Corp. (NASDAQ: DYAX), a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of biotherapeutics for oncology and inflammatory indications. The company uses phage display, a drug discovery technology to identify antibody, small protein, and peptide compounds for clinical development. It offers DX-88, an ecallantide, which is in late stage clinical trial development in two indications. The advanced indication for DX-88 involves the treatment of hereditary angioedema, a life-threatening inflammatory condition, which completed three Phase II trials and two Phase III trials; and the second indication for DX-88 is for the prevention of blood loss during on-pump cardiothoracic surgery (CTS), which completed a Phase I/II trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. The company also has other biopharmaceutical discovery and development programs, primarily DX-2240, an antibody that targets Tie-1 receptor on tumor blood vessels; and DX-2400 antibody, an inhibitor that inhibits matrix metalloproteinase 14 on tumor cells and tumor blood vessels. It also provides patent licenses to other biopharmaceutical and pharmaceutical companies to use its phage display patents, to discover and develop biologic compounds for use in specified fields; offers library licenses to use its phage display libraries in connection with their internal therapeutic development programs; and performs funded research for various collaborators. The company has co-development collaboration agreements with Athera, CSIRO, and Syntonix Pharmaceuticals; and licensing agreements with Cubist Pharmaceuticals, sanofi-aventis, and Fovea Pharmaceuticals. Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts.
First Advantage Corporation (NASDAQ: FADV) provides risk mitigation and business solutions in the United States and internationally. The companyas Lender Services segment offers credit reporting services, strategic marketing solutions, anti-fraud/identity verification tools, and broker certification services. Its Data Services segment provides transportation credit reporting, motor vehicle record reporting, criminal records reselling, specialty finance credit reporting, and lead generation services. This segment also offers driver history reports, vehicle registration, credit reports on cargo shippers and brokers, individualsa credit reports, and membership-based consumer products and services. The companyas Dealer Services segment provides specialized credit reporting and automotive lead generation services. Its Employer Services segment offers employment background screening, hiring management systems, occupational health services, and tax incentive services. The companyas Multifamily Services segment provides resident screening services consisting of criminal and eviction records searches, credit reporting, employment verification, lease performance and payment histories; and rentersa insurance, property performance analytics, and property management software. Its Investigative and Litigation Support Services segment offers computer forensics, electronic discovery, due diligence reports, and other high level investigations. First Advantage Corporation serves mortgage lenders, automobile dealerships, real estate investment trusts, property management companies, providers of transportation services, insurance agents, national law firms, and non-profit organizations. The company was founded in 2003 and is headquartered in Poway, California. First Advantage Corporation is a subsidiary of The First American Corporation.
Carrols Restaurant Group, Inc. (NASDAQ: TAST), through its subsidiary, Carrols Corporation, engages in the ownership and operation of restaurants in the United States. As of December 31, 2008, it operated 315 quick-service restaurants as franchisee under the Burger King brand name in 12 Northeastern, Midwestern, and Southeastern states. The company also owned and operated 91 Pollo Tropical restaurants, of which 86 were in Florida, 4 were in New Jersey, and 1 was in Connecticut; and franchised 25 Pollo Tropical restaurants, including 21 in Puerto Rico, 2 in Ecuador, and 2 on college campuses in Florida. In addition, it owned and operated 154 Taco Cabana restaurants located primarily in Texas; and franchised 2 Taco Cabana restaurants in New Mexico, 1 in Georgia, and 1 in Texas. The company was formerly known as Carrols Holdings Corporation and changed its name to Carrols Restaurant Group, Inc. in November 2006. Carrols Restaurant Group, Inc. was founded in 1960 and is headquartered in Syracuse, New York.
Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that treat upper gastrointestinal diseases and disorders. Its products include Zegerid capsules and powder for oral suspension, which are proprietary immediate-release formulations that combine antacids and omeprazole (a proton pump inhibitor) to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD); and Glumetza for the treatment of type 2 diabetes. The company is also developing a Zegerid tablet formulation, Budesonide MMX for the treatment of mild or moderate active ulcerative colitis, and Rifamycin SV MMX for the treatment of traveleras diarrhea. It has strategic alliances with Schering-Plough to develop, manufacture, and sell Zegerid brand OTC products in the lower dosage strength of 20 mg of omeprazole in the United States and Canada; GlaxoSmithKline to develop, manufacture, and commercialize prescription and OTC products in approximately 100 countries, including in Africa, Asia, the Middle-East, and Central and South America; and Cosmo Technologies, Ltd, which grants Santarus exclusive rights to develop and commercialize Budesonide MMX and Rifamycin SV MMX for the United States market. The company sells its products to wholesale distributors in the pharmaceutical industry. Santarus was founded in 1996 and is based in San Diego, California.
ValueVision Media, Inc. (NASDAQ: VVTV), an integrated multi-channel retailer, markets, sells, and distributes its products directly to consumers through various forms of electronic media. Its principal electronic media activity is its television home shopping business, which uses on-air spokespersons to market brand name and private label consumer products. The company also markets an array of merchandise through its Internet retailing Web sites, ShopNBC.com and ShopNBC.TV, which provide a range of consumer merchandise, including various products being featured in its television programming. It sells jewelry, watches, consumer electronics, housewares, apparel, fashion accessories, cosmetics, health and beauty products, coins and collectibles, seasonal items, and other merchandise through its television network and Internet shopping Web sites. ValueVision Media has strategic alliances with GE Capital Equity Investments, Inc. and NBC Universal, Inc. The company was founded in 1990 and is based in Eden Prairie, Minnesota.
DURECT Corporation (NASDAQ: DRRX), a specialty pharmaceutical company, focuses on the development of pharmaceutical products for pain, central nervous system, disorders, cardiovascular disease, and other chronic diseases based on its proprietary drug formulations and delivery platform technologies. The companyas products include POSIDUR, a release formulation of bupivacaine under Phase IIb clinical trial, which is used for the treatment of post-surgical pain; and ELADUR, a transdermal bupivacaine patch under Phase IIb clinical trial that provides continuous delivery of bupivacaine for up to three days from a single application, as well as is used for the treatment of pain associated with post-herpetic neuralgia. It also offers Remoxy, an oral oxycodone gelatin capsule under development with pain therapeutics; and TRANSDUR-Sufentanil, a proprietary transdermal sufentanil patch under development, which provides continuous delivery of sufentanil for a period of up to seven days from a single application. In addition, the company offers CHRONOGESIC (sufentanil), a pain therapy system; and ALZET, the miniature implantable osmotic pumps and accessories for experimental research in mice, rats, and other laboratory animals, as well as conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies. Further, it designs, develops, and manufactures various biodegradable polymers based on lactide, glycolide, and caprolactone under the LACTEL brand for pharmaceutical and medical device clients for use as raw materials in their products. The company has collaboration agreements with Alpharma Ireland Limited; Nycomed Danmark, APS; Pain Therapeutics, Inc.; Endo Pharmaceuticals Inc; Voyager Pharmaceutical Corporation; ALZA Corporation; EpiCept Corporation; and NeuroSystec Corporation. DURECT Corporation was founded in 1998 and is based in Cupertino, California.
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com
One example from the SqueezeTrigger database is approximately 2.5 billion short sale transactions going back to January 1, 2005, and SqueezeTrigger calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com
Go to www.SqueezeTrigger.com to find out the exact price that the entire Total Short Interest will start covering!
About SQUEEZETRIGGER.COM
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each monthas short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
((Comments on this story may be sent to [email protected]))
Court Overturns SECās Annuities Rule, but Gives Agency Leeway to Re-establish It
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News